The company said the U.S. trial, known as COMMAND, is another step for its implantable Stentrode brain computer interface to become commercially available. Stentrode converts the thoughts associated with attempted movement into cursor and keyboard commands.

The trial will evaluate the safety and efficacy of Stentrode in six severely paralyzed patients in the U.S. for regaining digital communication and functional independence, the company said. Synchron is also continuing to evaluate the device in the SWITCH human clinical trial in Australia.